Spero Therapeutics (SPRO) Net Income towards Common Stockholders Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,228.66% |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | 48.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.06% |
| Dec 31, 2025 | 230.92% |
| Sep 30, 2025 | 58.28% |
| Jun 30, 2025 | 90.46% |
| Mar 31, 2025 | -9.58% |
| Dec 31, 2024 | -143.68% |
| Sep 30, 2024 | -454.02% |
| Jun 30, 2024 | -50.01% |
| Mar 31, 2024 | 4.59% |
| Dec 31, 2023 | 100.51% |
| Sep 30, 2023 | 72.14% |
| Jun 30, 2023 | 54.15% |
| Mar 31, 2023 | 55.98% |
| Dec 31, 2022 | 200.22% |
| Sep 30, 2022 | 48.89% |
| Jun 30, 2022 | -40.68% |
| Mar 31, 2022 | -56.10% |
| Dec 31, 2021 | -46.30% |
| Sep 30, 2021 | -18.13% |
| Jun 30, 2021 | -0.38% |
| Mar 31, 2021 | 14.52% |
| Dec 31, 2020 | 26.66% |
| Sep 30, 2020 | -8.01% |
| Jun 30, 2020 | -38.43% |
| Mar 31, 2020 | -313.85% |
| Dec 31, 2019 | -141.18% |
| Sep 30, 2019 | -68.04% |
| Jun 30, 2019 | -33.44% |
| Mar 31, 2019 | 48.73% |
| Dec 31, 2018 | 28.24% |
| Sep 30, 2018 | 13.36% |
| Jun 30, 2018 | 17.86% |
| Mar 31, 2018 | -49.28% |
| Dec 31, 2017 | -77.25% |
| Sep 30, 2017 | -62.97% |